Pat Furlong

Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy

Yetrib Hathout, Edward N. Brody, Paula R. Clemens et al. · Proceedings of the National Academy of Sciences · 2015 · 289 citations

The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

F Mindlen, Roberto Nordaby, M I Soto Ruiz et al. · Queensland's institutional digital repository (The University of Queensland) · 1996 · 154 citations

Non-pharmacological Intervention, Preventive Medicine, Cardiovascular Disease +10

Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Craig M. McDonald, Eduardo Marbán, Suzanne Hendrix et al. · The Lancet · 2022 · 78 citations · Full text

A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy

Ronald G. Victor, H. Lee Sweeney, Richard S. Finkel et al. · Neurology · 2017 · 73 citations · Full text

Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy

Stephen Lynn, Annemieke Aartsma‐Rus, Kate Bushby et al. · Neuromuscular Disorders · 2014 · 45 citations · Full text

Clinical Effectiveness, Duchenne Muscular Dystrophy, Medicine +5